Elo Mutual Pension Insurance Co Sells 674 Shares of DexCom, Inc. (NASDAQ:DXCM)

Elo Mutual Pension Insurance Co reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,630 shares of the medical device company’s stock after selling 674 shares during the period. Elo Mutual Pension Insurance Co’s holdings in DexCom were worth $3,926,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Amalgamated Bank increased its stake in DexCom by 1.1% in the 2nd quarter. Amalgamated Bank now owns 84,778 shares of the medical device company’s stock valued at $9,612,000 after buying an additional 891 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of DexCom by 9.4% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,976 shares of the medical device company’s stock worth $678,000 after buying an additional 512 shares during the last quarter. SYSTM Wealth Solutions LLC grew its holdings in shares of DexCom by 10.3% in the second quarter. SYSTM Wealth Solutions LLC now owns 25,201 shares of the medical device company’s stock valued at $2,857,000 after acquiring an additional 2,344 shares in the last quarter. E Fund Management Co. Ltd. lifted its holdings in DexCom by 6.5% during the second quarter. E Fund Management Co. Ltd. now owns 5,455 shares of the medical device company’s stock worth $618,000 after acquiring an additional 331 shares during the period. Finally, Mutual of America Capital Management LLC lifted its holdings in DexCom by 2.3% during the second quarter. Mutual of America Capital Management LLC now owns 55,054 shares of the medical device company’s stock worth $6,242,000 after acquiring an additional 1,229 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,483 shares of company stock valued at $201,708. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Up 0.8 %

Shares of DXCM opened at $69.46 on Thursday. The business’s 50-day moving average price is $79.87 and its 200-day moving average price is $110.26. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $27.62 billion, a PE ratio of 44.81, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company earned $0.34 earnings per share. DexCom’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on DXCM shares. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Oppenheimer decreased their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Robert W. Baird increased their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.